{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:16:39Z","timestamp":1783304199559,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal Muscular Atrophy (SMA) is a rare, inherited neuromuscular disorder characterized by progressive muscle wasting and imposing a significant clinical and economic burden on both patients and health care systems. Although global research on SMA is expanding, limited evidence is available from low- and middle-income countries, including Iran. This study aimed to provide a comprehensive profile of patients with SMA in Iran using self-reported data, with a focus on clinical characteristics, economic burden, and patterns of healthcare utilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted among 73 patients with SMA identified through the national SMA patient advocacy association. Data were collected via structured telephone interviews using a pre-tested questionnaire covering seven domains: sociodemographic characteristics, clinical profile, and health care utilization as prescribed by physicians, direct medical and non-medical costs. Descriptive analysis was performed using SPSS (v23).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 73 participants (49.3% female), the majority had SMA Type 2 (63.0%) and were older than 10 years (97.3%). Hospitalization was reported by 52.1% of patients, with SMA-related admissions incurring significantly higher costs (average costs: $240.764) and longer stays. Regarding disease-modifying therapy, 56.2% received SMN-targeted treatments. Perceived efficacy assessments revealed that 72% and 81.25% of Nusinersen and Risdiplam -treated patients reported \u201cgood or significant\u201d clinical improvement, respectively. Outpatient service use was variable: 49.3% had never received occupational therapy, and 74.0% had not engaged in physiotherapy. General practitioner (GP) visits were more common (68.5%), while consultations with pulmonologist and cardiologist visits were infrequent (24.7% and 27.4%, respectively). Only 19.2% reported having annual preventive check-ups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings underscore considerable heterogeneity in service utilization and economic burden among patients with SMA in Iran. the underuse of rehabilitation and specialist care may reflect access barriers or financial constraints. There is a critical need for national strategies to improve early diagnosis, ensure equitable access to therapies, and integration of SMA care into existing health insurance frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04366-7","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:46:57Z","timestamp":1778492817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported clinical characteristics and healthcare utilization in Spinal Muscular Atrophy (SMA): a cross-sectional study from Iran"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0679-9609","authenticated-orcid":false,"given":"Bita","family":"Montazeri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0487-4114","authenticated-orcid":false,"given":"Rajabali","family":"Daroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3173-9065","authenticated-orcid":false,"given":"Ali","family":"Darvishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-569X","authenticated-orcid":false,"given":"Morteza","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-2393","authenticated-orcid":false,"given":"Majid","family":"Anabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-6397","authenticated-orcid":false,"given":"Ramin","family":"Heshmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"5","key":"4366_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/bioe.12695","volume":"34","author":"C Gyngell","year":"2020","unstructured":"Gyngell C, Stark Z, Savulescu J. Drugs, genes and screens: The ethics of preventing and treating spinal muscular atrophy. Bioethics. 2020;34(5):493\u2013501.","journal-title":"Bioethics"},{"key":"4366_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance. Application Clin Genet. 2021;14:11\u201325.","journal-title":"Application Clin Genet"},{"issue":"7","key":"4366_CR3","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","volume":"152","author":"TW Prior","year":"2010","unstructured":"Prior TW, Snyder PJ, Rink BD, Pearl DK, Pyatt RE, Mihal DC, et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet Part A. 2010;152(7):1608\u201316.","journal-title":"Am J Med Genet Part A"},{"issue":"3","key":"4366_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns7030045","volume":"7","author":"T Kimizu","year":"2021","unstructured":"Kimizu T, Ida S, Okamoto K, Awano H, Niba ETE, Wijaya YOS, et al. Spinal Muscular Atrophy: Diagnosis, Incidence, and Newborn Screening in Japan. Int J Neonatal Screen. 2021;7(3):45.","journal-title":"Int J Neonatal Screen"},{"issue":"9630","key":"4366_CR5","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333.","journal-title":"Lancet"},{"issue":"1","key":"4366_CR6","first-page":"1","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(1):1\u201310.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4366_CR7","first-page":"e200310","volume":"14","author":"M Schroth","year":"2024","unstructured":"Schroth M, Deans J, Arya K, Castro D, De Vivo DC, Gibbons MA, et al. Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations. Neurology: Clin Pract. 2024;14(4):e200310.","journal-title":"Neurology: Clin Pract"},{"issue":"1","key":"4366_CR8","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J market access health policy. 2019;7(1):1601484.","journal-title":"J market access health policy"},{"key":"4366_CR9","doi-asserted-by":"crossref","unstructured":"Chan SH, Wong CK, Wu T, Wong W, Yu MK, Au IC, et al. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data. Eur J Health Econ. 2022:1\u201310.","DOI":"10.1007\/s10198-022-01548-5"},{"key":"4366_CR10","doi-asserted-by":"crossref","unstructured":"Marcellusi A, Bini C, Casiraghi J, D\u2019Ambrosio F, Rotundo MA, Pallara A, et al. Cost of illness of spinal muscular atrophy (SMA) in Italy. Glob Reg Health Technol Assess. 2019;2019:2284240319867662.","DOI":"10.1177\/2284240319867662"},{"issue":"3","key":"4366_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.36469\/63185","volume":"6","author":"H Tan","year":"2019","unstructured":"Tan H, Gu T, Chen E, Punekar R, Shieh PB. Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy. J health Econ outcomes Res. 2019;6(3):185.","journal-title":"J health Econ outcomes Res"},{"issue":"1","key":"4366_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-017-0695-0","volume":"12","author":"J L\u00f3pez-Bastida","year":"2017","unstructured":"L\u00f3pez-Bastida J, Pe\u00f1a-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):1\u20137.","journal-title":"Orphanet J Rare Dis"},{"key":"4366_CR13","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40273-019-00769-6","volume":"37","author":"S Zuluaga-Sanchez","year":"2019","unstructured":"Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, et al. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. PharmacoEconomics. 2019;37:845\u201365.","journal-title":"PharmacoEconomics"},{"key":"4366_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11:1\u20139.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4366_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000009715","volume":"95","author":"GM Chambers","year":"2020","unstructured":"Chambers GM, Settumba SN, Carey KA, Cairns A, Menezes MP, Ryan M, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020;95(1):e1\u201310.","journal-title":"Neurology"},{"key":"4366_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40258-020-00624-2","volume":"19","author":"E Landfeldt","year":"2021","unstructured":"Landfeldt E, Pechmann A, McMillan HJ, Lochm\u00fcller H, Sejersen T. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021;19:501\u201320.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"4366_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s41983-024-00921-w","volume":"60","author":"M Babaee","year":"2024","unstructured":"Babaee M, Vahidi Ara S, Vahidi H, Jafari N, Zeinali V, Farahbakhsh N, et al. Framework and overview of the Pediatric Spinal Muscular Atrophy Registry Program of Iran. Egypt J Neurol Psychiatry Neurosurg. 2024;60(1):153.","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"issue":"2","key":"4366_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/JND-221614","volume":"10","author":"V Mansouri","year":"2023","unstructured":"Mansouri V, Heidari M, Bemanalizadeh M, Azizimalamiri R, Nafissi S, Akbari MG, et al. The first report of Iranian registry of patients with spinal muscular atrophy. J Neuromuscul Dis. 2023;10(2):211\u201325.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"4366_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41043-025-00738-0","volume":"44","author":"BD Teli","year":"2025","unstructured":"Teli BD, Behzadifar M, Beiranvand M, Rezapour A, Ehsanzadeh SJ, Azari S, et al. The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study. J Health Popul Nutr. 2025;44(1):16.","journal-title":"J Health Popul Nutr"},{"issue":"1","key":"4366_CR20","first-page":"35","volume":"9","author":"S Dunaway","year":"2016","unstructured":"Dunaway S, Montes J, McDermott MP, Martens W, Neisen A, Glanzman AM, et al. Physical therapy services received by individuals with spinal muscular atrophy (SMA). J Pediatr Rehabil Med. 2016;9(1):35\u201344.","journal-title":"J Pediatr Rehabil Med"},{"issue":"1","key":"4366_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/jisprm.jisprm_4_19","volume":"2","author":"AI Foead","year":"2019","unstructured":"Foead AI, Yeo WWY, Vishnumukkala T, Larvin M. Rehabilitation in spinal muscular atrophy. J Int Soc Phys Rehabilitation Med. 2019;2(1):62\u201370.","journal-title":"J Int Soc Phys Rehabilitation Med"},{"issue":"4","key":"4366_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.34172\/doh.2023.30","volume":"14","author":"R Khabiri","year":"2023","unstructured":"Khabiri R. A brief overview on the health insurance situation in Iran. Depiction Health. 2023;14(4):393\u20136.","journal-title":"Depiction Health"},{"key":"4366_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1052-2","volume":"14","author":"HW Wan","year":"2019","unstructured":"Wan HW, Carey KA, D\u2019Silva A, Kasparian NA, Farrar MA. Getting ready for the adult world: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14:1\u201313.","journal-title":"Orphanet J Rare Dis"},{"key":"4366_CR24","doi-asserted-by":"publisher","first-page":"1032474","DOI":"10.3389\/frhs.2022.1032474","volume":"2","author":"W Hanney","year":"2022","unstructured":"Hanney W, Munyon M, Mangum L, Rovito M, Kolber M, Wilson A. Perceived barriers to accessing physical therapy services in Florida among individuals with low back pain. Front Health Serv. 2022;2:1032474.","journal-title":"Front Health Serv"},{"issue":"1","key":"4366_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10198-024-01678-y","volume":"26","author":"T Sejersen","year":"2025","unstructured":"Sejersen T, Graham S, Ekstr\u00f6m A-B, Kroksmark A-K, Kwiatkowska M, Ganz ML, et al. Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden. Eur J Health Econ. 2025;26(1):35\u201348.","journal-title":"Eur J Health Econ"},{"key":"4366_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s41669-018-0093-0","volume":"3","author":"J Cardenas","year":"2019","unstructured":"Cardenas J, Menier M, Heitzer MD, Sproule DM. High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1 (SMA1): retrospective analysis of the kids\u2019 inpatient database (KID). PharmacoEconomics-open. 2019;3:205\u201313.","journal-title":"PharmacoEconomics-open"},{"issue":"6","key":"4366_CR27","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","volume":"41","author":"C Kokaliaris","year":"2024","unstructured":"Kokaliaris C, Evans R, Hawkins N, Mahajan A, Scott DA, Sutherland CS, et al. Long-term comparative efficacy and safety of risdiplam and nusinersen in children with type 1 spinal muscular atrophy. Adv Therapy. 2024;41(6):2414\u201334.","journal-title":"Adv Therapy"},{"issue":"6","key":"4366_CR28","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/22143602241288087","volume":"11","author":"MR Ashrafi","year":"2024","unstructured":"Ashrafi MR, Babaee M, Hashemi Nazari SS, Barzegar M, Ghazavi M, Beiraghi Toosi M, et al. Comparative efficacy of risdiplam and nusinersen in Type 2 and 3 spinal muscular atrophy patients: A cohort study using real-world data. J Neuromuscul Dis. 2024;11(6):1190\u20139.","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"4366_CR29","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.jval.2024.03.420","volume":"27","author":"J Kleintjens","year":"2024","unstructured":"Kleintjens J, Patel A, Howells R, McHale P, Affinito S, Bischof M. EE121 Economic Consequences of Persistence and Adherence to Lifelong Therapy for Patients with Presymptomatic Spinal Muscular Atrophy (SMA). Value Health. 2024;27(6):S79\u201380.","journal-title":"Value Health"},{"key":"4366_CR30","doi-asserted-by":"crossref","unstructured":"Yaftian F, Mobinizadeh M, Olyaeemanesh A, Mohamadi E. Is it ethical to reimburse SMA innovative treatments from government resources? 2023.","DOI":"10.21203\/rs.3.rs-3795930\/v1"},{"key":"4366_CR31","doi-asserted-by":"crossref","unstructured":"Chelogoi DN, Jonyo FO, Amadi H. The influence of socio-cultural factors in access to healthcare in Kenya: a case of Nairobi County, Kenya. J Social Political Sci. 2020;3(3).","DOI":"10.31014\/aior.1991.03.03.208"},{"issue":"1","key":"4366_CR32","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1186\/s12913-024-12069-7","volume":"24","author":"F Moradi","year":"2024","unstructured":"Moradi F, Karami B, Soofi M, Karamimatin B, Jalili F, Akbari S, et al. Healthcare utilization among people with disabilities in Iran: what predictors are associated with medical visits? BMC Health Serv Res. 2024;24(1):1637.","journal-title":"BMC Health Serv Res"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04366-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04366-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:05:36Z","timestamp":1783303536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04366-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4366"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04366-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was part of a Ph.D. thesis that is supported by Azad University of Medical Sciences (Code: IR.IAU.PS.REC.1402.525).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"This was not a clinical study, although all participants in the study answered the questions voluntarily. The authors confirmed that informed consent was obtained from all subjects. The authors confirm that all methods were performed following the relevant guidelines and regulations e.g., the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"Bita Montazeri affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency statement"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"238"}}